Bicycle Therapeutics Plc ADR(BCYC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.73 | Insider Own | 9.89% | Shs Outstand | 50.4M | Perf Week | 8.68% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | 4.82% | Insider Trans | -0.64% | Shs Float | 45.4M | Perf Month | 6.3% |
| Enterprise Value | -0.30B | PEG | - | EPS next Q | -0.4 | Inst Own | 63.84% | Short Float | 7.61% | Perf Quarter | -3.24% |
| Income | -0.19B | P/S | 3.2 | EPS this Y | 23.13% | Inst Trans | -1.08% | Short Ratio | 8.44 | Perf Half Y | -17.97% |
| Sales | 0.06B | P/B | 0.53 | EPS next 5Y | 6.97% | ROA | -26.41% | Short Interest | 3.45M | Perf YTD | -45.2% |
| Book/sh | 7.31 | P/C | 0.38 | EPS past 3/5Y | 5.87% -3.36% | ROE | -32.23% | 52W High | -57.27% ($9.08) | Perf Year | -52.8% |
| Cash/sh | 10.12 | P/FCF | - | Sales past 3/5Y | 71.38% 47.36% | ROIC | -36.23% | 52W Low | 16.51% ($3.33) | Perf 3Y | -73.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 22.48% | Gross Margin | 91.36% | Volatility(W/M) | 5.12% 5.84% | Perf 5Y | -92.78% |
| Dividend TTM | - | EV/Sales | -4.9 | Sales Y/Y TTM | 215.59% | Oper. Margin | -387.53% | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.08 | EPS Q/Q | 37.41% | Profit Margin | -311.16% | RSI (14) | 56.25 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.08 | Sales Q/Q | -78.68% | SMA20 | 5.76% ($3.67) | Beta | 1.6 | Target Price | $10.14 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/7/30 | SMA50 | 0.72% ($3.85) | Rel Volume | 1.07 | Prev Close | $3.78 |
| Employees | 288 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -25.09% -85.33% | SMA200 | -15.51% ($4.59) | Avg Volume(3M) | 0.41M | Price | $3.88 |
| IPO | 2019/5/23 | Option/Short | Yes/Yes | Trades | 2884 | Volume | 436,250 | Change | 2.65% |
🧬 Bicycle Therapeutics (BCYC) is a clinical-stage biotech company developing novel cancer therapeutics based on its proprietary bicyclic peptide platform. Headquartered in the UK and listed in the US via ADR, the company leverages its unique modality of conjugating drugs to synthetic peptides to advance both solid tumor therapeutics and radiopharmaceutical pipelines.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
BCYC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +23.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $320. Peers typically go for $1,089.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 63.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #304 of 594 in the industry
Based on market cap of $195M.
ACOG#301 Alpha Cognition Inc $200M PER - 
PRQR#302 ProQR Therapeutics N.V $199M PER - 
WHWK#303 Whitehawk Therapeutics Inc $197M PER - BCYC#304 Bicycle Therapeutics Plc ADR $195M PER - 
ZNTL#305 Zentalis Pharmaceuticals Inc $195M PER - 
FAQ
What kind of company is BCYC?
BCYC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BCYC?
The market cap of BCYC is approximately $195M, ranking 4,046 within its sector.
What is the 52-week high and low for BCYC?
BCYC has recorded a 52-week high of $9.08 and a low of $3.33.
